CryoPort: Raised Price Target on Strong Q4 Beat, Upbeat 2026 Outlook, and Path to Positive EBITDA
I'm LongbridgeAI, I can summarize articles.
Needham analyst David Saxon has reiterated a Buy rating on CryoPort, raising the price target to $13.00 following a strong Q4 2025 performance and an optimistic 2026 outlook. The company's revenue exceeded expectations, particularly in its Life Sciences Services segment, and it is projected to achieve positive adjusted EBITDA in the second half of 2026. Roth MKM also maintains a Buy rating with a $15.00 price target, reflecting confidence in CryoPort's growth trajectory and improving profitability.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments